Dmitry Kaminskiy is the Founding Partner of Deep Knowledge Life Sciences, which is specifically focused on disruptive geroscience and preventive medicine startups aiming to extend healthy longevity with cutting-edge biomedical and AI technologies.
Dmitry Kaminskiy is a frequent speaker on the topics of AI and Longevity. During the last few years he spoke at conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Global Pharmaceutical and Biotechnology Conference”, at the "Precision Medicine World Conference" in Silicon Valley, as well as several others at Oxford and Cambridge Universities.
One of Dmitry’s major interests is anti-aging and healthy longevity, which he has engaged in business, research, and public activities. He is the Managing Trustee of the Biogerontology Research Foundation, a leading UK think tank supporting the development of geroscience and healthy longevity. Dmitry’s announcement of a $1 million USD prize for the first person to reach their 123rd birthday was covered by Forbes, as well as other top business media outlets.
Deep Knowledge Life Sciences has been the lead investor in a number of promising geroscience companies, including Insilico Medicine, a pioneer in applying AI and deep learning to age-related biomarker and drug discovery (and the consortium of companies around Insilico, including Youth Laboratories and Longensis), and five other companies in the fields of Geroscience, NeuroTech, Preventive Medicine, and Longevity focused Mobile Apps.